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Introduction
Repair of carotid stenosis in additional to best medical
therapy (BMT) is currently the best way to treat most
asymptomatic patients with 60e99% carotid stenosis.
Carotid stenosis causes preventable strokes. The unfortu-
nates who present with stroke due to carotid stenosis (and
their even more unfortunate counterparts who experienced
a fatal stroke as the first sign of trouble) all harboured an
asymptomatic lesion prior to their respective events. Carotid
repair used judiciously in concert with BMT and performed
well, can have life-long protective effects against stroke-* This paper is also being published in the Journal of Vascular
Surgery 52/2 (2010) 445-54, doi’s:10.1016/j.jvs.2010.05.063,
10.1016/j.jvs.2010.05.064.
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doi:10.1016/j.ejvs.2010.05.004related death and disability for patients with asymptomatic
carotid stenosis.1e3 There is a difference between critical
analysis and being unreasonably critical. Reckless claims
have been made about the superiority of BMT alone for
60e99% carotid stenosis.4e7 Small patient cohorts including
minor lesions with limited follow up have done ‘well’ with
BMT alone and that has been used to advocate the cessation
of carotid repair.8e13 Practitioners have been accused of self
enrichment as the motivation for carotid repair.14 We are
proudly informed that in the UK, only 20% of patients
undergoing CEA are being treated for asymptomatic carotid
stenosis, while many times that number who could benefit
from repair will go on to have preventable stroke.14,15
This leads to the following points.
1) Each time repair plus BMT has been compared to BMT
alone, repair has had significant and lasting benefits.1e3
There are numerous current organizational guidelines
recommending repair and detailing the benefits
(Table 1).16e19
2) Anyone who believes that they are performing carotid
repair for their own benefit and not for the benefit of
the patient should stop doing it immediately.14
3) BMT has produced stroke reduction in a variety of
populations but has not been well tested among good
risk patients with significant asymptomatic carotid
stenosis who would otherwise be candidates for
repair.5,8,9,20e24
4) Repair has also improved due to patching and medical
management and has been performed with lower riskd by Elsevier Ltd. All rights reserved.
Asymptomatic Carotid Artery Stenosis 275than before (Table 2).1,2,25e28 Antiplatelet agents and
statins have made repair as much as 50% safer.26,29e32
The small long-term annual risk of ipsilateral stroke of
about 0.5% in repair patients may be even smaller when
BMT is optimized.
5) Current research will help guide therapy by identifying
those most likely to benefit from repair in addition to
BMT and those who are at high risk for repair and
therefore, less likely to benefit.7,10,11,13,26,33,34
6) Consideration should be given to a randomized trial of
BMT alone versus BMT plus repair but this will likely
take a decade to plan and conduct.What is the evidence for repair (in addition to
medical management)?
After a significant carotid stenosis has developed, that
lesion remains a threat to the patient until it is removed. In
the ACST, for example, the annual risk of stroke after repair
(0.55%) was much less than the annual risk with BMT alone
(1.9%).1 Both the ACAS and ACST studies compared CEA plus
BMT versus BMT alone, and both studies demonstrated
a decreased risk of stroke by approximately 50% at 5 years,
even though both studies were biased against repair.1,2
The risk of repair is front-loaded and the downside is
evident within 30 days. BMT is ‘pay-as e you e go’ and the
risks only become evident over time. The risk of BMT alone
is subject to underestimation if there is loss to follow up,
death of undetermined cause, small patient cohorts or
crossover to repair. Both of ACAS and ACST grossly under-
estimated the long-term benefits of repair for some of
these reasons and by curtailing follow up soon after the
benefit of repair had been determined. Had patients been
followed longer, the benefit of repair would likely have
been greater since the annual risk of stroke after repair was
much less than the annual risk with BMT alone.3 To put it
another way, any patient that lived more than a couple
years experienced a benefit to carotid repair every year for
the rest of their lives while every patient who did not
undergo repair continued to face an excess annual threat.
In addition, it is possible that contemporary BMT, not fully
implemented during ACST (by conclusion of the trial 70%
were on statins), would further decrease the small annual
risk of stroke after repair. We will learn more about this
from CREST.35
Repair plus BMTwas shown to be the better treatment in
ACST, even though the study was biased against CEA. Only
91% of patients randomized to repair received it and 18% of
those randomized to BMT underwent repair. Technique andTable 1 Guidelines from various organizations for repair of asy
American Academy of Neurology (2005) Stenosis 60e
the perioper
American Heart Association (1998) Stenosis 60e
performed w
European Society of Vascular Surgery (2009) CEA recomm
years of age
rate is <3%.
Society for Vascular Surgery (2008) Stenosis 60eperioperative management were not standardized. Had all
CEA patients been on statins and antiplatelet agents and
received a patch at surgery, risk would likely have been
lower.28,29,32 Contemporary results of CEA show improve-
ment and are in the range of 1.5% stroke/death risk (Table
2). The perioperative risk of stroke and death for CEA in
asymptomatic patients in CREST were low and will serve as
a benchmark.35 CAS is a maturing procedure and has
improved significantly over the past several years and will
likely continue to improve as we better understand
appropriate patient selection. Data available for CAS in
asymptomatic patients outside of CREST comes from high
risk registries. For example, among 516 asymptomatic
patients with high risk anatomy for CEA, the perioperative
stroke/death rate for CAS was 1.8%.36 The ACT 1 study is
continuing to enroll standard risk asymptomatic patients
randomized to BMT plus CEA or CAS. In the lead in phase,
the stroke/death rate for CAS was 1.3% with no ipsilateral
strokes between 30 days and 1 year.37Alternative methods
of cerebral protection, such as reversed flow, may also play
a role.38e40
Effort has been devoted to understand which patients
are most likely to benefit from repair. This will decrease the
number needed to treat to prevent a stroke. High risk
groups are being identified, including those with; silent
infarcts, certain plaque characteristics, microemboli on
Transcranial Doppler (TCD), rapid plaque progression and
others.7,10,12,13,34,41
The bottom line: BMT plus repair was much better than
BMT alone, even in a level 1 study biased against repair.
BMT has improved, but other things have changed as well.
As long as the perioperative risk of repair remains about the
same as or less than the risk of BMT alone at 2 years, it will
continue to benefit good risk patients to consider repair in
addition to BMT.
What is the evidence for BMT alone?
We have no level 1 data showing that BMT alone in any era
has been better than BMT plus repair. We don’t know if the
risk of BMT alone is low enough to obviate the benefits of
repair. Shouldn’t we know the answer to that before we
abandon the patients who could benefit from repair? The
assertion that BMT has solved the problem of asymptomatic
carotid stenosis comes from several recent studies; SMART,
Oxford Vascular, ACSRS and studies by Spence and
Abbott.7e9,11,12 These studies are not adequate to deter-
mine care.
The SMART Study, an often cited source for the
supremacy of BMT, followed 221 patients withmptomatic carotid stenosis.
99%. CEA can reduce future stroke rate if
ative complication rate is kept low.16
99%. CEA indicated when it can be
ith less than 3% stroke and death rate.17
ended in asymptomatic men with <75
with 70e99% stenosis, if the perioperative stroke and death
CEA should be considered in younger, fit women.18
99%, CEA plus BMT, if the perioperative risk is low.19
Table 2 Perioperative risk of carotid endarterectomy in patients with asymptomatic carotid stenosis.
Year Patients Stroke Death Stroke/death
ACAS2 1995 724 e e 2.3%
ACST1 2004 1348 e e 2.8%
US National Inpatient Sample25 2008 111,684 0.88% 0.38% e
No. New England Vascular Group26 2008 1732 e e 1.4%
NSQIP27 2009 5009 0.96% 0.56% 1.7%
276 P.A. Schneider, A.R. Naylorquestionnaires.8 Many of these patients would not be
considered for repair, since a peak systolic velocity (PSV) of
only 150 cm/s was required to be included. Only 96 patients
had a 70e99% stenosis, with a PSV > 210 cm/s. Stroke
occurred in 2.7% over 3.6 years but 6% had CEA and 1% had
CAS and deaths due to stroke were included in the general
category of death (15%) and we don’t know how many
deaths were stroke-related. The Oxford Vascular Study
reported a 0.34% ipsilateral stroke rate per year with BMT
alone.9 Another 1.8% per year developed ipsilateral tran-
sient ischemic attacks and many went on to have CEA.
Other territory strokes occurred in 8.3% per year. Unspec-
ified vascular death occurred in 7.7%. There were 101
patients with 50% stenosis followed in the study but only
32 patients had 70e99% stenosis. In another line of inves-
tigation, Spence used TCD to identify asymptomatic carotid
stenosis patients (PSV  170 cm/s) with and without
microemboli.7 Those with microemboli had a stroke risk of
10.3% the first year and 18.5% the second year. One can only
guess why all the microemboli patients were not referred
for CEA after the first year. In those who did not have
microemboli, the first year risk of stroke was 1.4% and the
second year risk of stroke was 1.8%. Although Spence
advocates against repair in this group (those remaining
after the high risk microemboli patients are excluded), the
cumulative 2 year risk of stroke was approximately 3.2%
with contemporary BMT alone. This is only a little less than
the 2 year stroke in the all-comers BMT group in the ACST
(about 4%) and is more than twice as high as the peri-
operative risk of CEA plus BMT in the CREST Trial.35 When
other end points were included (stroke or death or CEA) in
those with no microemboli, the risk was 6.5% at 2 years.
Even in the lower risk, no microemboli group, the benefit of
repair in addition to BMT could be significant if repair is
provided at a low risk, in the range of 2% or less. In another
study, Abbott did not show such a dramatic difference
between those with and without microemboli on TCD.12 The
microemboli group had an annual TIA/stroke risk of 10% and
in the group with no microemboli it was 7%. Both these
groups would likely benefit from repair as long as it can be
done with low risk. ACSRS followed 462 patients who had
60% stenosis in relationship to bulb diameter (ECST
method e these could be 30% diameter reduction by NAS-
CET criteria). CT scans were performed to identify those
with silent cerebral infarcts. The ipsilateral annual event
rate was 4.6% when infarcts were present and 2.4% when no
infarcts were present. The annual risk of stroke was 3.6%
with and 1% without silent infarcts.10
The above studies have been used to extrapolate a trend
and suggest a stroke rate approaching zero with modern
BMT.4 This is duly noted but is an indirect evidence of thebenefits of BMT. These studies were generally compromised
by a number of recurring problems; inclusion of minimal
lesions, unclear endpoints, mixed groups, short-term follow
up, and only small groups with bonafide carotid stenosis
that would have been considered for repair. In each of the
aforementioned studies, for example, duplex was used to
quantify carotid stenosis. The last time that a major
asymptomatic carotid study carefully analyzed degree of
stenosis by angiography, was in the follow up of NASCET
patients with asymptomatic contralateral carotid
stenosis.42 The stroke rate was 3.2% per year and the
highest risk was in those with 75e94% stenosis (18.5% stroke
at 5 years). Incidentally, 80% of the strokes were not
preceded by TIA. Calls for the cessation of repair are being
made on the basis of these data, without much acknowl-
edgment of the challenges of BMT alone.
BMT is desirable and necessary and is discussed as if it was
fully formed and possible to broadly implement. In fact, BMT
is not simple to characterize or to produce; it is challenging to
accomplish in broad populations because it is expensive, time
consuming, complicated, requires vigilance and compliance
and has its own side-effects and complications.43 There are
those who will not be able to quit smoking and those who
cannot tolerate statins or antiplatelet agents. Not everyone
will be convinced to take flax seed and grapefruit juice.
Today’s BMTwill be tomorrow’s obsoletepractice.What is the
real world risk of stroke with BMT alone, especially over the
long term, given that there will be noncompliance and
intolerance that reduce the efficacy of themedical regimen?
Compliance with a complex medical regimen will likely be
higher in a study where investigators go about proving biases
with impractically labor intensivepractices but likely lower in
the realworld.Whereas in the realworld, youhaveeither had
your carotid fixed or not. In addition to the disadvantages of
BMT, there is a downside to lack of repair; continued annual
risk of stroke in excess of the annual risk after repair,
psychological effects of living with a threatening lesion, and
the potential of long-term cognitive deterioration.44e48
Drawing ridiculous conclusions from skimpy evidence,
some have called for a cessation or severe limitation of
carotid repair.4,5,49 It is disingenuous to treat small groups
of asymptomatic patients with non-lesions, to see that they
remain asymptomatic with BMT and then claim victory. The
old risks of repair are being compared with pseudo-natural
history studies of modern BMT in patients with lesions that
might never have been considered for repair. All the while,
those with carotid stenosis could go on to have preventable
strokes without repair under a misguided and nihilistic
approach. Incidentally, what is the late follow up of
medically managed patients who still harbor these lesions?
We don’t have any.
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Patients that present with stroke due to carotid stenosis, at
some previous time had an asymptomatic lesion and an
opportunity for repair. Repair of carotid stenosis, by CEA
and in some cases CAS, in addition to BMT is currently the
best way to treat most asymptomatic patients with 60e99%
carotid stenosis. How well can BMT alone handle the
problem? This will take a trial and 10 years. What we know
now is that each time it was fairly evaluated, when repair
was added to BMT, it cuts the risk in half. When repair is
used judiciously in concert with BMT and performed well, it
can have life-long protective effects against stroke-related
death and disability for patients with asymptomatic carotid
stenosis. We should continue to provide repair to good risk
patients with significant asymptomatic carotid stenosis and
continue to look for ways to identify which patients are
most likely to benefit from repair.
Part II: The Majority of Patients with
Asymptomatic Carotid Disease do not Require
Intervention and Are Better Treated Medically
- Professor A. Ross Naylor.
Keywords: Carotid; Asymptomatic; Surgery; Stent; Medical
Therapy
Introduction
Thomas Kuhn invented the term ‘paradigm shift’. This
occurs when “scientists tend to work within one set of
ideas about how the world is. Everything they do, be it
experimental or theoretical, is informed by, and framed
within, that set of ideas. However, there will be evidence
that does not fit. At first, that evidence will be ignored or
sabotaged. Eventually though, the anomalies will pile up
so high that they simply cannot be ignored or sabotaged
any longer. Then comes crisis”.50 In this debate, I will
contend that ‘anomalous’ evidence challenges the ‘one
size fits all approach to treating asymptomatic carotid
disease. We need a paradigm shift in thinking’.
In the 1970s, surgeons were convinced that carotid
endarterectomy (CEA) prevented stroke in asymptomatic
patients. Their intuition was vindicated with the Asymp-
tomatic Carotid Atherosclerosis Study (ACAS)2 and the
Asymptomatic Carotid Surgery Trial (ACST),1 leading the
American Heart Association (AHA) to conclude that CEA was
“recommended in highly selected patients with high-grade
asymptomatic stenoses, provided it was performed by
surgeons with <3% morbidity & mortality”.17 This is
generally translated to mean “CEA is appropriate in
asymptomatic patients with 60e99% stenoses”.
The AHA recommendation (updated in 200651) is based
on the highest level of evidence; so why the debate?
Unlike the symptomatic trials (which provided Level I
evidence for intervention and enduring multi-disciplinary
consensus), there is less agreement about managing
asymptomatic patients. Notwithstanding the conserva-
tism of some Neurologists, the only issue for many
Surgeons/Interventionists is whether CEA or carotid arterystenting (CAS) is now the preferred intervention. In their
world, CEA significantly reduces the risk of stroke by 50%
and that (alone) is compelling enough evidence for inter-
vening. Using Kuhn’s principle, they are “working within
one set of ideas about how the world is”. They are also
hostile to anyone who suggests that their reasoning might
be flawed.
The AHA recommendation includes the phrase “highly-
selected”. Unfortunately, no clarification was forthcoming
about what this meant and physicians have to interpret this
for themselves (in reality it is ignored). However, defining
who benefits most (and least) from intervention is crucial to
this debate and brings us to those anomalies that challenge
current guidelines and support a paradigm shift in thinking.
These are chronologically listed in Table 3 and the most
important will be debated after reviewing how critics
responded to them.
Physicians have (not unreasonably) adopted the role of
patient advocate should anyone suggest that intervention
might be unnecessary; (i) “you would never send someone
home with occlusive disease of the left main coronary
artery; why then would you send home a patient with
a critical stenosis of a dominant hemisphere internal
carotid with a 95% stenosis?”,53 (ii) “it is politically unten-
able to deny women, and not men prophylactic CEA”54 and
(iii) “but what about the patient? He understands that his
brain is threatened by a severe carotid stenosis, no matter
what the overall percentage of this threat actually is. They
should also understand that denying surgery equates to
being exposed life long to a cumulative risk of a cerebro-
vascular event”.55 Vox populi comments include; (i) “as
long as 80% of strokes are not preceded by a TIA, I will treat
asymptomatic patients”, (ii) “women live longer, therefore
it is unreasonable to withhold CEA/CAS”, (iii) “patients are
not always compliant with taking medications. It is safer to
offer CEA” and (iv) “surgeons need to focus on the welfare
of the individual and not the population”. Next comes
media hype; a classic example being the 1994 New York
Times commentary (following the ACAS Alert) which stated
that “50% fewer strokes will occur if asymptomatic indi-
viduals with >60% stenoses are submitted to surgery”.57
This, I suspect, is a commonly quoted statistic when risk:-
benefit is discussed with patients. It is also a good example
of being ‘economical with the actualite´’.
Methodological criticisms include; “as experts in this
domain, we should rely on strong, though not necessarily
fully evidence based arguments and draw our own conclu-
sions about the case of our specific patient”,55 (ii)
“subgroup analyses can be ignored as the trials were never
powered to make these conclusions” and (iii) “these data
are from very old studies and have little relevance in
today’s world, especially now CAS is available.” Realities of
professional life (conceded ‘off the record’) include; “if I
do not operate on this patient, someone else will and I will
lose income”. Finally, if all else fails, why not resort to
censure; (i) “why should we, who work in a first-world
health service, pay any attention to someone working in
a third-world system” (2005 Charing Cross Symposium) and
(ii) “what is more paradoxical is the attitude of some who
become progressive opinion leaders, despite the fact that
the message they deliver is a deliberate and insistent non-
operating pleading in the case of asymptomatic disease.
Table 3 ‘Anomalies’ regarding a ‘one size fits all’ policy of offering CEA (or CAS) to ‘standard risk’ patients with 60e99%
asymptomatic carotid stenoses.
1991 ACAS: 40% of surgeon applicants rejected, raising questions about generalisability67
1995 ACAS: with a 2.3% procedural risk, CEA prevents only 59 strokes at 5 years per 1000 CEAs2
ACAS: with procedural risk included, CEA conferred no benefit in women2
ACAS: no relationship between stenosis severity/bilateral disease and late stroke risk2
Even if you could treat every patient, 95% of all strokes in the community will still occur56
1996 Hertzer concedes that the annual risk of stroke in ACAS was much lower than expected68
ACAS: even with the procedural risk excluded, CEA still conferred no benefit in women69
First editorial to question whether ACAS results warrant a tenfold increase in CEA numbers70
1997 Canadian Neurologists & Stroke Physicians recommend against CEA & screening71
2000 ACAS: CEA does not confer significant benefit in patients with a contralateral occlusion72
55% of late strokes are cardioembolic or lacunar; ie majority are not due to ICA embolism73
2001 7/10 US States report procedural risks >3% following CEA74
Using ACST entry criteria; the average procedural risk after CEA in 10 US states was 5.9%74
2002 ACAS; had their data been analysed at 4 years, CEA would have conferred no benefit70
2003 European Stroke Initiative suggests that medical treatment is now probably the best option75
Editorial suggests that the randomized trials should be repeated76
2004 ACST: CEA conferred no benefit in patients aged >75 years1
ACST: no association between stenosis severity/bilateral disease and late stroke risk1
ACST: if procedural risk included, CEA conferred no significant benefit in women60
ACST: most of the benefit was seen in patients with a pre-randomisation cholesterol >6.5.1
Using ACST inclusion criteria, the average procedural risk after CEA in 10 US states was 5.4%78
Meta-analysis of 46 contemporary surgical studies found mortality  8 higher and death/stroke  3
higher compared with outcomes in ACAS77
2005 92% of all carotid revascularisations in USA are now performed in asymptomatic patients25
2007 US Task Force recommends against screening (benefits too low and do not outweigh risks)59
Annual risk of stroke in medically treated patients has been decreasing over the last 20 years6
2008 Published evidence that high statin therapy stabilises asymptomatic carotid plaques33,34
Even with 15 yr follow up it is never cost effective to offer CEA to females, irrespective of age79
NEJM poll: 50% of respondents worldwide would treat asymptomatic patients conservatively63
Editorial suggests that it may be time to stop intervening in asymptomatic patients49
If the procedural risk of death/disabling stroke exceeded 2.1%, or if the annual rate of
fatal/disabling stroke was <1.09%, CEA/CAS will not confer any long term benefit62
2009 Systematic Review; non-interventional therapy now safer than CEA/CAS (attributed to improvements in
medical therapy) and is 3e8 times more cost-effective4
94% of CEA/CAS procedures in USA are ultimately unnecessary, costing $2.1 billion pa14,61
Evidence of sustained decline in annual stroke risk in medically treated patients in ACAS & ACST14
2010 Evidence that high statin therapy significantly reduces spontaneous embolisation7
Meta-analysis of 3 recent studies (1635 patients); ipsilateral stroke risk now only 0.5% per year9
More calls for randomized trials comparing CEA with CAS to include a third medical limb14,52,65,66
278 P.A. Schneider, A.R. NaylorUsing mostly statistical or economic arguments, rather than
medical evidence, they aim to demonstrate that prophy-
lactic CEA, even in being probably the safest approach in
skilled hands, was not medically justified, nor cost-effec-
tive for public savings”.56 Ouch!.
The preceding counterarguments to Table 30s anomalies
mask a growing crisis, primarily because some are now too
important to remain ignored. Firstly; ACAS/ACST showed
that almost 90% of medically treated patients were never
destined to suffer a stroke within 5 years.1,2 That should, of
course, make me winner in this debate (read the title), but
I see you remain unconvinced. Second, is the uncomfort-
able observation that even if you could treat everyone
fulfilling ACAS criteria with a 2.3% procedural risk; 95% of
strokes will still happen.14,56 This is because CEA/CAS
cannot prevent the 70% of strokes unrelated to carotid
disease, while two-thirds of carotid origin strokes will not
have significant stenoses and 15e20% will present witha TIA. That leaves about 8e10 patients whose strokes will
be attributable to significant, asymptomatic carotid disease
in whom to target interventions.58 However, CEA reduces
stroke by 50%,1,2 so that only 5 strokes (at most) will be
prevented. Consider that the next time someone justifies
‘mass intervention’ because ‘80% of strokes are
unheralded’.
If you still believe that CEA/CAS confers benefit in the
majority of asymptomatic patients, have you considered
the logistics of finding and treating them? With a population
of 1.3 million, let us assume that Peter Schneider and his
colleagues can somehow identify the 1% of Hawaiians
(13,000) with an asymptomatic 60e99% stenosis (this would
normally take years). Assuming theatres/catheter suites
work every week-day (260 pa) and 10 CEA/CAS procedures
are performed somewhere on the island on every one of
these days (i.e., 2600 interventions in asymptomatic
patients per year; quite a big ask), it would take five years
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a stroke whilst awaiting treatment and more ‘at-risk’
populations will emerge. In reality, a policy of operating
upon as many asymptomatic patients as possible will only
prevent about 1% of all strokes.
But ‘mass interventions’ consume resources. Using ACAS
data, performing CEA/CAS with a 2.3% risk prevents 59
ipsilateral strokes/1000 procedures at 5 years14 (indisput-
able fact). The number of ‘any’ strokes preventedZ 51. In
2005, 122,986 revascularisations were undertaken in
asymptomatic patients in the USA25 and simple maths
(59  122.986) show that only 7256 patients will have
ipsilateral strokes prevented. This also means that in 2005,
115,730 (94%) underwent an ultimately unnecessary inter-
vention. Using US financial data,25 unnecessary interven-
tions cost US Health Providers $2.1 billion each year.14,61
That is surely unsustainable.
Ah, but you probably feel that my debate has focussed
excessively on logistics, ‘cold’ statistics and expenditure
and not enough upon the individual patient? No, I would not
allow that. Notwithstanding the 30þ anomalies detailed in
Table 3, the single most important reason why a paradigm
shift in thinking is unavoidable is because the most vener-
ated of ‘sacred cows’ is under threat. That is the assump-
tion that the annual rate of stroke in medically treated
patients remains about 2%. If the annual risk has decreased
since ACAS/ACST published, many of the risk:benefit
calculations become vulnerable to challenge. If the annual
risk falls to 1%, it is unlikely that CEA/CAS could ever confer
significant benefit.62 What would you think if I suggested
that the annual risk of ipsilateral stroke may now be as low
as 0.5e0.7%?
Abbott was one of the first to observe that the annual
risk of stroke in medically treated patients has declined
significantly over the last 20 years4,6,49 and her latest meta-
analysis concludes that non-interventional therapy is the
safer option, whilst also being more cost-effective.4 A
second (smaller) meta-analysis published in 2010 included
natural history data from three studies recruiting after 2000
and found that the average annual risk of ipsilateral stroke
in 1635 medically treated patients was 0.5%.9 Abbott (and
others) have attributed this decline in stroke risk to
improvements in BMT, especially through the use of high
dose statins.4,7,14,20,33,34 Not surprisingly, this has elicited
the inevitable counter-argument64 (recognise a trend?),
primarily because some studies in Abbott’s meta-analysis
included patients with 50e99% as opposed to 60e99%
stenoses.64 However, neither ACAS/ACST, nor a raft of
natural history studies has consistently shown that late
stroke is associated with stenosis severity.1,2,14 Moreover,
an alternative interpretation of data from ACAS and ACST
suggests that they (too) have encountered year on year
reductions in stroke risk. They just haven’t acknowledged it
yet.
ACAS published five-year data in 1995, ACST in 2004 and
then released 6e10 year data during 2008/2009,1,2,14 giving
observers three sequential five-year periods for compar-
ison. In 1995, ACAS reported a five-year risk of ‘any’ stroke
of 17.5% (i.e., 3.5% pa) in medically treated patients. The
risk of ‘any’ stroke in years 1e5 of ACST fell to 11.8% (i.e.,
2.4% pa), while in the second five-year period of study (i.e.,
years 6e10 of ACST), the risk of ‘any stroke’ decreased to7.2% (i.e., 1.4% pa). In 1995, ACAS reported a five-year risk
of ‘ipsilateral’ stroke of 11.0% (i.e., 2.2% pa) in medically
treated patients. By 2004, the five-year risk of ‘ipsilateral’
stroke in ACST had fallen to 5.3% (i.e., 1.1% pa), while in
the second five-year period (i.e., years 6e10 of ACST), the
risk of ‘ipsilateral stroke’ decreased to 3.6% (i.e., 0.7% pa).
This means that the average annual risk of ‘any’ stroke has
declined by 60% from 3.5% to 1.4% in 15 years since ACAS
published, while the annual average risk of ‘ipsilateral’
stroke has declined by 67% from 2.2% to 0.7%. This, in
conjunction with Abbott’s meta-analysis, suggests that
there has been a significant, sustained decrease in the
annual risk of stroke.
So who will win this debate? The paradox is that I can
neither win nor lose. Until influential bodies (i.e., the AHA)
consider the implications of a declining stroke risk and revise
their recommendation (i.e., triggering a paradigm shift in
thinking), nothingwill change. This is because the AHAwields
the greatest influence over practice worldwide and
Surgeons/Interventionists will continue to offer ‘mass
interventions’, not least to minimise medico-legal censure.
To many observers,4,14,52,65,66 (including the Principle
Investigator of CREST66) we need to undertake an adequately
powered randomized trial which includes treatment arms for
CEA, CAS and BMT. This should make it possible to test algo-
rithms for identifying ‘high risk for stroke’ subgroups (e.g.,
TCD embolisation, silent infarction on CT, incomplete circle
of Willis, computerised plaque morphology, biomarkers).
Surely we must focus resources towards intervening in only
a very small cohort of ‘high risk for stroke’ patients?
Conversely, it is also true that I cannot lose this debate. It
is indisputable that the vast majority of patients with
asymptomatic carotid diseasewill never suffer a stroke, only
1% of strokes will be prevented through a mass campaign of
uncritical intervention, 94% of interventions in asymptom-
atic patients are ultimately unnecessary and the annual risk
of stroke is now verymuch lower than itwas in 1995. Howelse
could you interpret the data? Unless, of course, you remain
distracted by other conflicts of interest.
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